share_log

What 4 Analyst Ratings Have To Say About Instil Bio

Benzinga Real-time News ·  Dec 12, 2022 15:02

Within the last quarter, Instil Bio (NASDAQ:TIL) has observed the following analyst ratings:

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings02200
Last 30D00100
1M Ago01000
2M Ago01100
3M Ago00000

These 4 analysts have an average price target of $11.5 versus the current price of Instil Bio at $0.8211, implying upside.

Below is a summary of how these 4 analysts rated Instil Bio over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

This current average represents a 33.33% decrease from the previous average price target of $17.25.

Stay up to date on Instil Bio analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

How Are Analyst Ratings Determined?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment